Other News To Note

Oramed Pharmaceuticals Inc., of Jerusalem, was awarded a NIS2.9 million (US$807,000) grant from the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of Israel. The funding will support development of Oramed's oral insulin and oral GLP-1 analogue for diabetes.